The comparative analysis of copy number variation data for methHigh and methLow groups (TCGA-PRAD; Firehose Legacy) showed that prostate tumors with higher levels of USP44 promoter methylation are characterized by a higher fraction of genome altered (p < 0.0001; Figure 3A). This evidence concerns the gene USP44 and prostate neoplasm.